ELTX - CIK 0001601485
The table below shows Elicio Therapeutics, Inc.'s balance sheet line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & equivalents | $18.56M | $17.62M | $12.89M | $50.49M | $88.76M |
| Short-term investments | - | - | - | - | - |
| Receivables | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Total current assets | $19.31M | $20.69M | $16.35M | $51.43M | $91.25M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Property, plant & equipment |
| $295.00K |
| $483.00K |
| $717.00K |
| $273.00K |
| $451.00K |
| Goodwill | - | - | - | - | - |
| Total assets | $25.86M | $28.18M | $27.15M | $52.79M | $96.51M |
| Accounts payable | $672.00K | $1.04M | $4.37M | $2.72M | $4.71M |
| Total current liabilities | $8.11M | $11.52M | $9.77M | $6.37M | $11.30M |
| Long-term debt | $9.41M | - | - | - | $0.00 |
| Total liabilities | $24.23M | $39.49M | $15.77M | $9.02M | $15.01M |
| Retained earnings | -$233.67M | -$194.10M | -$142.20M | -$253.94M | -$215.13M |
| Total equity | $1.64M | -$11.31M | $11.37M | $43.77M | $81.51M |